Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group. Barnes E, et al. Among authors: selby r. Nat Med. 2023 Jul;29(7):1760-1774. doi: 10.1038/s41591-023-02414-4. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414897 Free PMC article.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, Snowden JA, Lim SH, Bowden SJ, Billingham L, Richter A, Carroll M, Carr EJ, Beale R, Rea D, Parry H, Pirrie S, Lim Z, Satsangi J, Dunachie SJ, Cook G, Miller P, Basu N, Gilmour A, Hodgkins AM, Evans L, Hughes A, Longet S, Meacham G, Yong KL, A'Hearne MJ, Koh MBC, Burns SO, Orchard K, Paterson C, McIlroy G, Murray SM, Thomson T, Dimitriadis S, Goulston L, Miller S, Keillor V, Prendecki M, Thomas D, Kirkham A, McInnes IB, Kearns P; OCTAVE-DUO investigators. Goodyear CS, et al. Lancet Rheumatol. 2024 Jun;6(6):e339-e351. doi: 10.1016/S2665-9913(24)00065-1. Epub 2024 May 8. Lancet Rheumatol. 2024. PMID: 38734019 Free article. Clinical Trial.
Testing for the lupus anticoagulant: the good, the bad, and the ugly.
Favaloro EJ, Pasalic L, Selby R. Favaloro EJ, et al. Among authors: selby r. Res Pract Thromb Haemost. 2024 Mar 18;8(3):102385. doi: 10.1016/j.rpth.2024.102385. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38623474 Free PMC article.
Cyto-swapping in maize by haploid induction with a cenh3 mutant.
Bortiri E, Selby R, Egger R, Tolhurst L, Dong S, Beam K, Meier K, Fabish J, Delaney D, Dunn M, Mcnamara D, Setliff K, Castro Miranda Lunny R, Gergen S, Dawe RK, Kelliher T. Bortiri E, et al. Among authors: selby r. Nat Plants. 2024 Apr;10(4):567-571. doi: 10.1038/s41477-024-01630-1. Epub 2024 Mar 18. Nat Plants. 2024. PMID: 38499777
Correction: Ivermectin and doxycycline treatments against Onchocerciasis: Adaptations and impact among semi-nomadic population in Massangam Health District, Cameroon.
Nditanchou R, Dixon R, Chailloux A, Atekem K, Biholong B, Wilhelm A, Selby R, Oye J, Kamgno J, Boakye D, Schmidt E, Senyonjo L. Nditanchou R, et al. Among authors: selby r. PLoS Negl Trop Dis. 2024 Feb 22;18(2):e0011980. doi: 10.1371/journal.pntd.0011980. eCollection 2024 Feb. PLoS Negl Trop Dis. 2024. PMID: 38386952 Free PMC article.
290 results